T-cell lymphomas represent about 15% of non-Hodgkin lymphomas, with a many sub-categories, and an important biological diversity.
It is a very heterogeneous lymphoma type with a large range of treatments. It may be difficult to diagnose.
The clinical presentation of the disease includes lymph nodes, fever, skin rash, ou linked medical problems.
Recruiting LYSA studies
- Breast Implant-Associated Anaplastic Large Cell LymphomaFrench and Belgian record of incidences of Breast Implant-Associated Anaplastic Large Cell Lymphoma
Relapse or refractory
- TOTALPhase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance
- NIVEAUNivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU)
LYSA studies soon recruiting
- ALK + – OBS